Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page’s Revision tag was updated from v3.6.5 to v3.6.6, signaling a new version of the page content or its underlying template.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page now presents an error page indicating the content is unavailable, including the HTML skeleton and header/footer, which removes the study information and linked documents from view.SummaryDifference16%

- Check54 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, indicating a minor system update; no study details or visible content were altered.SummaryDifference0.1%

- Check76 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3, indicating a new site build. This change appears to be a minor platform update and does not reflect changes to the study content on this page.SummaryDifference0.1%

- Check83 days agoChange DetectedThe site software revision was updated from v3.6.0 to v3.6.2, indicating a minor release. No changes to the study details or visible page content are introduced.SummaryDifference0.1%

- Check97 days agoChange DetectedThe page now indicates that recruitment is closed and adds new help/navigation sections. The Intervention/Treatment label is updated, and the revision footer shows v3.6.0 compared to v3.5.5.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.